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Prevalence of hepatitis C virus (HCV) antibody has been re-
ported in Mexican Americans, but its prevalence in other US
Hispanic/Latino groups is unknown. We studied 2 popula-
tions of US Hispanic/Latino adults; 3210 from the National
Health and Nutrition Examination Survey (NHANES) 2007–
2010 and 11 964 from the Hispanic Community Health
Study/Study of Latinos (HCHS/SOL). Age-standardized
prevalence of HCV antibody was similar in NHANES 2007–
2010 (1.5%) and HCHS/SOL (2.0%) but differed significantly
by Hispanic/Latino background in HCHS/SOL (eg, 11.6% in
Puerto Rican men vs 0.4% in South American men). These
findings suggest that the HCV epidemic among US Hispan-
ics/Latinos is heterogeneous.
Keywords. hepatitis C virus; HCV; Hispanic; Latino;
United States; prevalence; antibody; RNA; risk factor.
Prevalence of hepatitis C virus (HCV) antibody in US popula-
tions, such as non-Hispanic/non-Latino Whites, non-Hispanic/
non-Latino Blacks, and persons of Mexican background, is
commonly estimated using data from the National Health and
Nutrition Examination Surveys (NHANES) [1–3]. NHANES
include substantial numbers of Mexican background par-
ticipants but relatively small numbers of Hispanic/Latino
participants from other backgrounds. Whether HCV antibody
prevalence differs between US Hispanic/Latino groups of dif-
ferent backgrounds is therefore not well understood.
During 2008–2011 Hispanic/Latino adults from 4 US com-
munities (Bronx, Miami, Chicago, and San Diego) were recruit-
ed to participate in the Hispanic Community Health Study/
Study of Latinos (HCHS/SOL). In addition to Hispanic/Latino
background, HCHS/SOL interviews assessed many of the same
characteristics as NHANES. In this study we present data from
NHANES 2007–2010 and HCHS/SOL side by side to provide a
current picture of HCV antibody prevalence and correlates of
HCV infection in US Hispanics/Latinos.
MATERIALS ANDMETHODS
Study Populations
NHANES are nationally representative samples of the noninsti-
tutionalized US population conducted by the National Center
for Health Statistics (NCHS). NHANES 2007–2010 partici-
pants completed in-person interviews that assessed demo-
graphics and many aspects of health and behavior; those over
the age of 19 also provided information on drug use and sexual
behaviors. NHANES 2007–2010 oversampled individuals of all
Hispanic/Latino backgrounds, but only Hispanics/Latinos of
Mexican background were enrolled in sufficient numbers to
permit separate analyses of this group [4]. Hispanic/Latino
NHANES participants who were not of Mexican background
were classified as “Other Hispanic.”
NHANES protocols were approved by the NCHS Research
Ethics Review Board, and all participants provided informed
consent. NHANES 2007–2010 included 20 686 participants of
whom 6875 were Hispanic/Latino. Because HCHS/SOL recruit-
ed individuals 18–74 years of age, we excluded 3388 NHANES
2007–2010 Hispanics/Latinos with ages outside this range. Also
excluded were 277 participants without HCV antibody data.
HCHS/SOL is a study of 16 415 Hispanic/Latino adults re-
cruited from 4 US communities (Bronx, Miami, Chicago, and
San Diego) [5, 6]. Participants completed physical examinations,
in-person interviews, and provided blood samples. Interviews
did not include questions related to drug use or sexual behaviors.
The HCHS/SOL protocol was approved by each local institu-
tional review board, and all participants provided informed
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consent. In total, 2694 participants recruited early in the study
were not asked to provide consent for HCV testing and were
not tested for HCV. A further 1502 participants were not tested
for HCV because consent for HCV testing was not provided in
time for inclusion in the testing panel. Also excluded were 213
participants who refused consent, 6 participants older than 74
years of age, 11 participants whose HCV testing had not been
completed, and 25 participants with indeterminate HCV anti-
body results.
We compared 11 964 HCHS/SOL participants included in
the analysis to those who were excluded. There were no differ-
ences by age and sex (both P≥ .05). However, there were differ-
ences by geographic region and Hispanic/Latino background
(both P < .01), which reflect the timeline by which consent for
HCV testing was introduced into the 4 recruitment sites. Spe-
cifically, included participants were more likely to be of Cuban
background and less likely to be of Puerto Rican background
than those excluded.
Laboratory Methods
The VITROS Anti-HCV assay (Ortho Clinical Diagnostics,
Raritan, NJ) was used to test NHANES samples for antibody
directed against HCV. Positive samples were repeated in dupli-
cate, and repeatedly positive samples were confirmed using the
CHIRON RIBA HCV 3.0 SIA assay (Bio-Rad Laboratories,
Hercules, CA). HCV antibody-positive samples were tested for
HCV RNA using the COBAS AMPLICOR HCV Test, v2.0
(Roche Molecular Diagnostics, Pleasanton, CA).
The ADVIA Centaur HCV immunoassay (Siemens Diagnos-
tics, Deerfield, IL) was used to perform HCV antibody testing
in HCHS/SOL. If the HCV immunoassay was positive, the
Abbott RealTime HCV assay (Abbott Molecular, Des Plaines,
IL) was used to test for HCV RNA. If the HCV RNA test result
was negative, the sample was retested with the CHIRON RIBA
HCV 3.0 SIA assay (Bio-Rad Laboratories, Hercules, CA) to
confirm the result of the immunoassay.
Statistical Methods
Prevalence estimates of HCV antibody overall and within strata
of interest were calculated using sampling weights provided by
NHANES 2007–2010 and HCHS/SOL. To enable comparison
of prevalence estimates from the two studies, we age-standard-
ized the weighted prevalence estimates by the direct method
using data from the US 2010 Census. To facilitate interpreta-
tion, throughout the article we refer to age-standardized
weighted prevalence of HCV antibody as “HCV prevalence.”
Survey-weighted χ2 tests were used to assess differences in
HCV prevalence between strata. Prevalences of HCV in
NHANES 2007–2010 and HCHS/SOL were compared by cal-
culating a standardized rate ratio and its 95% confidence inter-
val (CI). Survey-weighted logistic regression was used to assess
whether demographic and behavioral characteristics had
independent associations with HCV prevalence. Prevalence of
HCV RNA is reported among those positive for HCV antibody
with nonmissing HCV RNA data.
RESULTS
Characteristics of the Study Populations
Fifty-two percent of the 3210 NHANES 2007–2010 Hispanics/
Latinos were male, and the median age was 36. The majority
(63%) were born outside the 50 US states, 63% were of Mexican
background, and 23% had incomes <$20 000. Forty percent of
the 11 964 HCHS/SOL participants were male, and the median
age was 47. The majority (83%) were born outside the 50 US
states, and 47% had incomes <$20 000. HCHS/SOL included
Hispanics/Latinos of multiple backgrounds: Mexican (39%),
Cuban (16%), Puerto Rican (15%), Dominican (9%), Central
American (11%), South American (7%), and mixed/other His-
panic/Latino (3%).
Prevalence of HCV by Demographic and Behavioral
Characteristics: NHANES 2007–2010 and HCHS/SOL
HCV prevalence was 1.5% (95% CI, 1.0–2.2, 47 HCV-seroposi-
tives) in NHANES 2007–2010 and 2.0% (95% CI, 1.6–2.4, 260
HCV-seropositives) in HCHS/SOL. HCV prevalence was
higher in men than women in both NHANES 2007–2010
(2.1% vs 0.9%, P < .01) and HCHS/SOL (2.9% vs 1.2%, P < .01).
Both NHANES 2007–2010 and HCHS/SOL identified men
40–69 years of age as the group with the highest prevalence of
HCV. Prevalence of HCV was, however, significantly (P < .05)
higher among men 50–59 years of age in HCHS/SOL (7.3%)
than in NHANES 2007–2010 (2.1%). Differences in age-
specific HCV prevalence between NHANES 2007–2010 and
HCHS/SOL women and among participants of Mexican back-
ground were not statistically significant.
Supplementary Tables 1 and 2 show HCV prevalence for
men and women, respectively, by characteristics assessed in
both NHANES 2007–2010 and HCHS/SOL. In HCHS/SOL,
HCV prevalence was highest in Puerto Rican background par-
ticipants (vs Mexican background participants, P < .01 for both
men and women) and lowest in South American background
participants (vs Mexican background participants, P < .05 for
both men and women). In NHANES 2007–2010, there was no
significant difference in HCV prevalence between Mexican
background participants and those of “Other Hispanic” back-
ground.
In logistic regression analyses that included all demographic
and behavioral characteristics as covariates, associations
between Puerto Rican and South American backgrounds and
HCV prevalence remained statistically significant in HCHS/
SOL men, whereas South American background remained sig-
nificant and Puerto Rican background was borderline sig-
nificant (P = .05) in HCHS/SOL women (Table 1). Other
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Table 1. Independent Associations Between Demographic and Behavioral Characteristics and Prevalence of HCV Antibody in HCHS/
SOL and NHANES 2007–2010 Hispanics/Latinos, Ages 18–74
HCHS/SOL NHANES 2007–2010


















18–29 0.03 (.01, .19) <.01 0.18 (.04, .78) .02 b b b b
30–39 0.21 (.09, .52) <.01 0.16 (.04, .59) .01 0.20 (.04, 1.18) .07 1.11 (.08, 15.27) .94
40–49 0.39 (.22, .72) <.01 0.62 (.32, 1.22) .17 2.20 (.76, 6.36) .14 1.44 (.22, 9.30) .69
50–59 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
60–69 0.44 (.20, .95) .04 2.52 (.81, 7.78) .11 1.64 (.43, 6.28) .46 2.67 (.54, 13.27) .22
70–74 0.20 (.05, .77) .02 0.36 (.07, 1.75) .21 b b b b
Recruitment Site
Bronx 1.0 Ref 1.0 Ref c c c c
San Diego 1.26 (.53, 3.02) .60 1.56 (.61, 4.01) .36 c c c c
Miami 0.68 (.15, 3.14) .62 0.86 (.11, 6.46) .88 c c c c
Chicago 0.38 (.18, .79) .01 0.44 (.21, .95) .04 c c c c
Hispanic/Latino background
Mexican 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
Central American 0.64 (.14, 2.97) .57 0.51 (.08, 3.07) .46 d d d d
Cuban 0.31 (.05, 1.76) .19 0.56 (.06, 5.50) .62 d d d d
Dominican 0.95 (.32, 2.83) .93 2.13 (.49, 9.19) .31 d d d d
Puerto Rican 4.92 (2.10, 11.53) <.01 2.90 (1.01, 8.30) .05 d d d d
South American 0.04 (.00, 0.39) <.01 0.07 (.01, .65) .02 d d d d
Mixed/other in HCHS/
SOL




e e e e 1.15 (.41, 3.26) .78 2.79 (.89, 8.79) .08
Interview language
Spanish 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
English 0.72 (.36, 1.47) .37 1.44 (.67, 3.12) .35 4.91 (1.46, 16.58) .01 3.43 (.79, 14.92) .10
Education
Less than high school 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
High school or
equivalent
1.68 (.94, 3.00) .08 1.09 (.57, 2.09) .78 0.95 (.21, 4.23) .95 0.42 (.07, 2.49) .33
More than high school 0.84 (.44, 1.57) .58 0.60 (.24, 1.50) .28 0.28 (.06, 1.27) .10 0.62 (.09, 4.29) .62
Nativity
Born outside the 50
states
1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref




1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
Single 1.85 (1.02, 3.34) .41 0.67 (.29, 1.55) 0.35 1.79 (.37, 8.58) .46 8.47 (2.02, 35.55) <.01
Separated, divorced, or
widow(er)
2.63 (1.40, 4.94) <.01 1.03 (.38, 2.79) .95 1.13 (.33, 3.80) .84 1.15 (.25, 5.28) .86
Annual household income
≥$20 000 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
<$20 000 1.37 (.86, 2.20) .19 1.47 (.68, 3.18) .33 4.15 (1.52, 11.32) .01 4.11 (.64, 26.36) .13
Health insurance
Yes 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
No 1.14 (.67, 1.95) .63 0.96 (.48, 1.91) .91 0.52 (.20, 1.33) .16 0.98 (.18, 5.33) .98
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characteristics with significant associations in multivariable
analyses of HCHS/SOL or NHANES 2007–2010 (Table 1) in-
cluded (1) current smoking (men and women in both studies),
(2) separated/divorced/widower vs married marital status (men
in HCHS/SOL), (3) English language interview vs Spanish
(men in NHANES 2007–2010), and (4) income <$20 000 (men
in NHANES 2007–2010).
Prevalence of HCV by High-Risk Behaviors: NHANES 2007–2010
HCV prevalence was significantly higher in individuals who re-
ported (i) using marijuana or hashish, (ii) using cocaine, heroin
or methamphetamine, (iii) having first sex at younger than 18
years, and (iv) having >10 sexual partners vs <5 partners in uni-
variable analyses. In logistic regression analyses that included ad-
justment for the characteristics shown in Supplementary Tables 1
and 2, the association with cocaine, heroin, or methamphetamine
use remained statistically significant (data not shown).
Prevalence of HCV by Recruitment Site and Hispanic/Latino
Background Group: HCHS/SOL
Participants in the Bronx had an HCV prevalence of 4.5%, sig-
nificantly higher than those in San Diego (1.7%), Chicago
(1.2%), and Miami (0.8%; P < .01 for the Bronx compared to
other sites). As shown in Figure 1, men and women of Puerto
Rican background in the Bronx had the highest HCV preva-
lence (14.2% and 4.1%, respectively). In comparison, HCV
prevalences among men and women of Puerto Rican back-
ground in Chicago were 4.7% and 1.3%, respectively.
Prevalence of HCV RNA in NHANES 2007–2010 and HCHS/SOL
Prevalence of HCV RNA was 53.2% in 41 NHANES 2007–
2010 Hispanics/Latinos and 73.2% in 260 HCHS/SOL Hispan-
ics/Latinos who were HCV-seropositive with HCV RNA data.
In HCHS/SOL, prevalence of HCV RNA was higher in men
than women (86.3% vs 55.2%, P < .01). No significant diffe-
rence in prevalence of HCV RNA by sex was seen in NHANES
2007–2010.
DISCUSSION
Age-standardized HCV prevalence among Hispanics/Latinos
18–74 years of age in NHANES 2007–2010 (1.5%) and HCHS/
SOL (2.0%) was similar to, if slightly higher than, prevalence
among non-Hispanic/non-Latino Whites (1.2%–1.5%) in
NHANES conducted between 1988 and 2008 [3]. However,
prevalence of HCV was high in those of Puerto Rican back-
ground, low in those of South American background, and in-
termediate in those of Mexican, Dominican, Cuban, and
Central American backgrounds (Supplementary Tables 1 and
2). These data signify that the scale of the HCV epidemic varies
between Hispanic/Latino background groups.
Many of the same associations with HCV prevalence were
observed in NHANES 2007–2010 and HCHS/SOL. For
example, English language interview, birth in the 50 US states,
and cigarette smoking were associated with significantly higher
HCV prevalence in men and women in both studies. However,
in multivariable analyses of HCHS/SOL that included
Table 1 continued.
HCHS/SOL NHANES 2007–2010


















Never 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
Former 2.45 (1.18, 5.11) .02 1.45 (.60, 3.49) .41 1.75 (.47, 6.48) .40 6.59 (2.23, 19.48) <.01
Current 7.94 (4.15, 15.19) <.01 5.38 (2.53, 11.44) <.01 4.64 (1.17, 18.34) .03 10.65 (3.08, 36.87) <.01
Alcohol use
Never 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
Former 1.39 (.54, 3.61) .49 0.93 (.33, 2.68) .90 0.49 (.04, 5.53) .55 0.99 (.08, 12.72) .99
Current 0.59 (.23, 1.51) .27 1.39 (.45, 4.29) .56 0.52 (.06, 4.88) .55 1.36 (.08, 22.38) .83
Abbreviations: CI, confidence interval; HCHS/SOL, Hispanic Community Health Study/Study of Latinos; HCV, hepatitis C virus; NHANES, National Health and
Nutrition Examination Survey.
a Results from a single survey-weighted multivariable logistic regression model that included all covariates shown in the table. Individuals with complete data on all
covariates are included.
b Values are not estimable because prevalence of HCV antibody in this group is 0.
c Recruitment site is not reported in NHANES 2007–2010.
d Values are not estimable because NHANES 2007–2010 groups participants who identify as Hispanic/Latino but not of Mexican background as “Other Hispanic.”
e The mixed/other Hispanic/Latino background group in HCHS/SOL includes those participants of mixed Hispanic/Latino background and also those participants who
did not identify as belonging to a specific Hispanic/Latino background group. This category is not equivalent to the “Other Hispanic” group in NHANES 2007–2010.
1588 • JID 2014:209 (15 May) • BRIEF REPORT
Hispanic/Latino background, associations between interview
language, nativity, and HCV prevalence became nonsignificant.
In contrast, interview language retained a significant associa-
tion and nativity had a marginal (P = .05) association with
HCV prevalence in multivariable analysis of NHANES men.
Together, these data suggest that differences in HCV prevalence
by language and nativity may actually reflect differences
between Hispanic/Latino background groups.
HCV prevalence was high among Puerto Rican background
participants in HCHS/SOL, and it is possible that some of their
HCV infections were acquired in Puerto Rico. For example, in
2001–2002, a population-based survey of adults in San Juan,
Puerto Rico, found that 10.6% of the male population was
HCV-seropositive and that 6.2% of adults (both men and
women) reported prior heroin use [7]. Alternatively, it could be
that participants of Puerto Rican background were primarily at
risk for HCV infection in the 50 US states, particularly in the
Bronx. A recent study of 9579 patients receiving care at Bronx
primary care clinics estimated HCV prevalence to be 4.6%–
7.7% [8]. These patients were predominantly women (72%)
and minority (51% Hispanic/Latino, 32% non-Hispanic/non-
Latino Black), with a mean age of 49 years [8]. In subgroup
analysis of this population, HCV prevalence was 14.8% among
1334 Hispanic/Latino men and 5.5% among 3581 Hispanic/
Latino women (William Southern, personal communication).
A similar study of 1000 primary care patients in a neighbor-
hood adjacent to the Bronx found that 8.3% were HCV sero-
positive [9].
There are several limitations that must be considered. First,
the proportion of eligible individuals who agreed to participate
was 41.7% in HCHS/SOL and 75.4% and 77.3% in NHANES
2007–2008 and NHANES 2009–2010, respectively. Although
both studies were weighted for nonresponse, it is possible that
individuals who declined to participate differed from those who
did participate, and that these differences were not controlled
through weighting procedures. Second, HCHS/SOL is not rep-
resentative of all US Hispanics/Latinos, and studies of Hispan-
ic/Latino populations in other areas could yield different
results. Indeed, the findings suggest that prevalence estimates of
HCV antibody in US Hispanics/Latinos depend on the specific
populations studied. For example, had more Puerto Rican back-
ground participants been included in the HCHS/SOL testing
panel, the estimated prevalence of HCV antibody in HCHS/
SOL might have been higher.
Overall, this study shows that the HCV epidemic among US
Hispanic/Latino adults is heterogeneous. This information will
be useful to those who direct public health resources for HCV
treatment and prevention. Clinicians who serve Hispanic/
Latino communities may also benefit from this information
because it highlights specific Hispanic/Latino groups that may
benefit from increased levels of HCV testing and treatment.
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